Uses of IL-4 in preparing medicament composition for treating chronic hepatic fibrosis

A technology of IL-4 and fibrosis, applied in the field of medicine

Active Publication Date: 2013-04-10
WEST VAC BIOPHARMA CO LTD
View PDF2 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no relevant report that IL-4 can effectively treat chronic liver fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Uses of IL-4 in preparing medicament composition for treating chronic hepatic fibrosis
  • Uses of IL-4 in preparing medicament composition for treating chronic hepatic fibrosis
  • Uses of IL-4 in preparing medicament composition for treating chronic hepatic fibrosis

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0039] The preparation of embodiment one IL-4

[0040] 1. Experimental animals: 30 Balb / c mice (purchased from the Experimental Animal Center of Sichuan University), females weighing 18-22 g in a circadian rhythm, free to eat and drink.

[0041] 2. Main reagent: ConA (Sigma Company, Type IV, number 066K7031). IL-4 homemade.

[0042] 3. Preparation of IL-4:

[0043] (1) Construction of engineering bacteria:

[0044] Design a pair of PCR primers, introduce the msc1 site at the 5' end of the target gene, and introduce the xho1 site at the 3' end to facilitate cloning between the msc1 and xho1 sites of the PET32a(+) vector. Use Taq DNA polymerase (Pyrobest, purchased from TaKaRa company) to carrier porf-mil4 (Invitrogen company) to carry out polymerase chain reaction (polymerase chain reaction, PCR) amplify to obtain mil-4 sequence, PCR product passes restriction endonuclease After digestion with msc1 and xho1 (Invitrogen), it was connected between the msc1 and xho1 sites of t...

Embodiment 2

[0049] Example 2 Treatment of chronic liver fibrosis with IL-4

[0050] A. Experimental modeling and experimental processing

[0051] 25 female Balb / c mice (body weight 18-22g) were randomly divided into five groups, 5 in each group: normal group, disease model group and treatment group (0.2ug / group, 1ug / group, 5ug / group) ,

[0052] Normal group of mice without any treatment;

[0053] The mice in the disease model group were subcutaneously injected with ConA 0.25mg / only (12.5mg / kg), once a week;

[0054]

[0055] After six weeks of continuous injection, blood was taken from the orbit, the serum was separated, and the serum was retained for detection by enzyme-linked immunosorbent assay (ELISA) method, and the serum enzyme indexes ALT and AST were measured; after the blood was taken, the mice were killed by pulling the neck. Liver tissues were collected for hematoxylin-eosin (HE) staining and Sirius red staining to observe the degree of inflammation and liver fibrosis.

...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention pertains to the field of biomedicine, and the technical problem that the invention solves is to provide a new use of IL-4, which particularly provides the use of IL-4 in preparing the drug combination for treating chronic liver fibrosis. When the dosage is 0.1ug / kg / d-5ug / kg / d, the effect for treating chronic liver fibrosis is good, thus providing a new choice for treating chronic liver fibrosis.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to the use of interleukin-4 (IL-4) in the preparation of a pharmaceutical composition for treating chronic liver fibrosis. Background technique [0002] Liver fibrosis is the common pathological basis for the further development of various chronic liver diseases. Its characteristic change is the imbalance between the formation and degradation of extracellular matrix (ECM), resulting in the excessive deposition of ECM and the formation of fibrosis, which in turn causes the remodeling of liver lobules. Pseudolobules and nodules form, entering the stage of cirrhosis [1,2]. Most chronic liver patients have varying degrees of fibrosis, of which 25% to 40% eventually develop into liver cirrhosis and even liver cancer. Since liver fibrosis is the last link from reversible pathological changes to irreversible pathological changes, blocking liver fibrosis has become a key issue in the tr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/20A61P1/16
Inventor 魏于全李炯
Owner WEST VAC BIOPHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap